Ondansetron HCl

Catalog No.S1390 Synonyms: GR 38032F

For research use only.

Ondansetron HCl (GR 38032F) is a serotonin 5-HT3 receptor antagonist, used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy.

Ondansetron HCl Chemical Structure

CAS No. 99614-01-4

Selleck's Ondansetron HCl has been cited by 2 Publications

1 Customer Review

Purity & Quality Control

Choose Selective 5-HT Receptor Inhibitors

Other 5-HT Receptor Products

Biological Activity

Description Ondansetron HCl (GR 38032F) is a serotonin 5-HT3 receptor antagonist, used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy.
Targets
5-HT3 [1]
In vivo Ondansetron decreases the intensity of withdrawal signs such as increased defecation, jumping and wet-dog shakes, elevated the nociceptive threshold values which are decreased by precipitated withdrawal, but produces no change in urination, rectal temperature or salivation. [1] Ondansetron and granisetron significantly enhances gastric emptying of glass beads and improves cisplatin-induced slowing of gastric emptying in rats. [2] Ondansetron exhibits a biphasic dose-response profile in mice, with antidepressant-like effects peaking at 0.1 mg/kg, in the forced swim and tail suspension tests. Ondansetron pretreatment augments the antidepressant effects of fluoxetine and venlafaxine but does not influence the effects of desipramine or 8-hydroxy-2-(di-n-propylamino) tetralin. Ondansetron (10 mg/kg) reverses hyperactivity in the open field, and decreases the percentage entry and time spent in open arms in the elevated plus maze. [3] Ondansetron, a selective and potent 5HT3 receptor antagonist, is shown to be effective at blocking the amphetamine-induced disruption of LI at a dose of 0.01 mg/kg, but not at 0.1 mg/kg. Ondansetron is able to attenuate increases in dopamine activity, produces pharmacologically with amphetamine without affecting baseline dopamine activity. [4] Ondansetron facilitates performance in young adult and aged animals, and inhibits an impairment in habituation induced by scopolamine, electrolesions or ibotenic acid lesions of the nucleus basalis magnocellularis. Ondansetron and arecoline antagonizes a scopolamine-induced impairment. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 66 mg/mL
(200.1 mM)
Water 24 mg/mL
(72.76 mM)
Ethanol 10 mg/mL
(30.31 mM)

Chemical Information

Molecular Weight 329.82
Formula

C18H19N3O.HCl

CAS No. 99614-01-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04226170 Recruiting Drug: DAS-001 Myasthenia Gravis DAS-MG Inc April 8 2021 Phase 2
NCT04610398 Recruiting Drug: Dexamethasone 4mg|Drug: NaCl 0.9% Pain Postoperative|Nausea Postoperative|Opioid Use Balgrist University Hospital March 11 2021 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Ondansetron HCl | Ondansetron HCl ic50 | Ondansetron HCl price | Ondansetron HCl cost | Ondansetron HCl solubility dmso | Ondansetron HCl purchase | Ondansetron HCl manufacturer | Ondansetron HCl research buy | Ondansetron HCl order | Ondansetron HCl mouse | Ondansetron HCl chemical structure | Ondansetron HCl mw | Ondansetron HCl molecular weight | Ondansetron HCl datasheet | Ondansetron HCl supplier | Ondansetron HCl in vitro | Ondansetron HCl cell line | Ondansetron HCl concentration | Ondansetron HCl nmr